Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma

Negishi,Takahito; Furubayashi,Nobuki; Takamatsu,Dai; Ieiri,Kousuke; Nishiyama,Naotaka; Kitamura,Hiroshi; Nakamura,Motonobu

doi:10.3892/ol.2020.12130

Radiographical efficacy of systemic treatment for bone metastasis from renal cell carcinoma

Authors:
- Takahito Negishi
- Nobuki Furubayashi
- Dai Takamatsu
- Kousuke Ieiri
- Naotaka Nishiyama
- Hiroshi Kitamura
- Motonobu Nakamura
View Affiliations

Affiliations: Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811‑1395, Japan, Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research University of Toyama, Toyama 930‑0194, Japan
Published online on: September 21, 2020 https://doi.org/10.3892/ol.2020.12130
Article Number: 267
Copyright: © Negishi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Enlarged bone metastasis from renal cell carcinoma (RCC) can cause skeletal‑related events, and thus treatment to inhibit the growth of bone metastases is often required. Although radiotherapy for RCC bone metastases can achieve a certain degree of local control, evidence is lacking regarding the effects of systemic therapy to improve bone metastasis. The present study aimed to assess the treatment efficacy of targeted therapy and immune checkpoint inhibitors, and to determine whether systemic therapy without radiotherapy can shrink bone metastases of RCC. The present study retrospectively reviewed 44 patients with RCC with bone metastases treated via systemic therapy, including targeted therapy or immune checkpoint inhibitors. Patients were divided into two groups: Those who underwent systemic therapy with radiotherapy for bone lesions (n=29); and those who underwent systemic therapy without radiotherapy for bone lesions (n=15). The radiographical efficacy of systemic therapy and the time to progression of bone metastases were compared between groups. The overall response rate of systemic therapy with radiotherapy was 44%, and in total, 13 patients demonstrated a partial response. Only one patient (6%) had a partial response among those who were treated via systemic therapy without radiotherapy. The time to progression of bone metastasis was 9.5 and 2.1 months in patients treated with and without radiotherapy, respectively (P<0.0001). Collectively, the present results suggested that targeted therapy or immune checkpoint inhibitors without radiotherapy had only a slight effect on bone metastasis control.

View Figures

View References

1	Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
3	Du YJ, Pahernik S, Hadaschik B, Teber D, Duensing S, Jäger D, Hohenfellner M and Grüllich C: Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. Urol Oncol. 34:433.e1–e8. 2016. View Article : Google Scholar
4	Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, et al: Distribution of metastatic sites in renal cell carcinoma: A population-based analysis. Ann Oncol. 23:973–980. 2012. View Article : Google Scholar : PubMed/NCBI
5	Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, et al: Natural history of malignant bone disease in renal cancer: Final results of an Italian bone metastasis survey. PLoS One. 8:e830262013. View Article : Google Scholar : PubMed/NCBI
6	Kinnane N: Burden of bone disease. Eur J Oncol Nurs (11 Suppl 2). S28–S31. 2007. View Article : Google Scholar
7	Mirels H: Metastatic disease in long bones: A proposed scoring system for diagnosing impending pathologic fractures. 1989. Clin Orthop Relat Res. (415 Suppl):S4–S13. 2003. View Article : Google Scholar : PubMed/NCBI
8	Ruppert LM: Malignant spinal cord compression: Adapting conventional rehabilitation approaches. Phys Med Rehabil Clin N Am. 28:101–114. 2017. View Article : Google Scholar : PubMed/NCBI
9	Umer M, Mohib Y, Atif M and Nazim M: Skeletal metastasis in renal cell carcinoma: A review. Ann Med Surg (Lond). 27:9–16. 2018. View Article : Google Scholar : PubMed/NCBI
10	Taunk NK, Spratt DE, Bilsky M and Yamada Y: Spine radiosurgery in the management of renal cell carcinoma metastases. J Natl Compr Cancer Netw. 13:801–809. 2015. View Article : Google Scholar
11	Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
12	Motzer RJ, Hutson TE, Tomczak P, Michaelson D, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
13	Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
14	Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
15	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
16	Woolf DK, Padhani AR and Makris A: Assessing response to treatment of bone metastases from breast cancer: What should be the standard of care? Ann Oncol. 26:1048–1057. 2015. View Article : Google Scholar : PubMed/NCBI
17	Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN and Ueno NT: Bone imaging in metastatic breast cancer. J Clin Oncol. 22:2942–2953. 2004. View Article : Google Scholar : PubMed/NCBI
18	McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC and Choueiri TK: Radium-223 dichloride in combination with vascular endothelial growth factor-targeting therapy in advanced renal cell carcinoma with bone metastases. Clin Cancer Res. 24:4081–4088. 2018. View Article : Google Scholar : PubMed/NCBI
19	Jehn CF, Diel IJ, Overkamp F, Kurth A, Schaefer R, Miller K and Lüftner D: Management of metastatic bone disease algorithms for diagnostics and treatment. Anticancer Res. 36:2631–2637. 2016.PubMed/NCBI
20	Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, Lin X, Fly K, Matczak E and Gore ME: Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 108:2470–2477. 2013. View Article : Google Scholar : PubMed/NCBI
21	Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer. 116:4256–4265. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kitamura H, Takahashi A, Takei F, Hotta H, Miyano N, Shindo T, Igarashi M, Tachiki H, Kunishima Y, Muranaka T, et al: Molecular-targeted therapy and surgery may prolong survival of renal cell carcinoma patients with bone metastasis: A multi-institutional retrospective study in Japan. Anticancer Res. 36:5531–5536. 2016. View Article : Google Scholar : PubMed/NCBI
23	Ruatta F, Derosa L, Escudier B, Colomba E, Guida A, Baciarello G, Loriot Y, Fizazi K and Albiges L: Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre. Eur J Cancer. 107:79–85. 2019. View Article : Google Scholar : PubMed/NCBI
24	Zekri J, Ahmed N, Coleman RE and Hancock BW: The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 19:379–382. 2001.PubMed/NCBI
25	Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, et al: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 17:917–927. 2016. View Article : Google Scholar : PubMed/NCBI
26	Morris ZS and Harari PM: Interaction of radiation therapy with molecular targeted agents. J Clin Oncol. 32:2886–2893. 2014. View Article : Google Scholar : PubMed/NCBI
27	Sharabi AB, Lim M, DeWeese TL and Drake CG: Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16:e498–e509. 2015. View Article : Google Scholar : PubMed/NCBI
28	Tokuhashi Y, Matsuzaki H, Oda H, Oshima M and Ryu J: A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 30:2186–2191. 2005. View Article : Google Scholar : PubMed/NCBI